_
Rehovot Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product
Pre-Validation Phase Showed Encouraging Results, Product Expected to be Launched in 2008
Rosetta Genomics, Ltd., a global leader in microRNA-based diagnostics and therapeutics, announced today it has successfully completed the prevalidation phase for its first diagnostic test. Using a single microRNA, the test is designed to differentiate squamous from non-squamous lung cancer with high sensitivity and specificity.
Rosetta Genomics diagnostic tests are currently undergoing validation testing at Columbia University Medical Center at its Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. The company expects three diagnostic tests to be launched in 2008 including a test for cancer of unknown primary, lung cancer vs. mesothelioma, and the squamous vs. non-squamous lung cancer test which has recently passed the prevalidation phase.
"The results we have seen so far for our microRNA-based diagnostic tests are very encouraging," Said Amir Avniel, President and CEO of Rosetta Genomics. "Results of the prevalidation phase showed the test differentiated squamous from non-squamous lung cancer using microRNA biomarkers identified by us, with both high sensitivity and specificity. We expect the test to be available for clinical use in the first half of 08."
About microRNAs
MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.
About Rosetta Genomics
Rosetta Genomics is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and other diseases
Source: Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product. Money.CNN.com PRNewswire-FirstCall (30 October 2007) [FullText and Forward-Looking Statement]
Rosetta Genomics, Ltd., a global leader in microRNA-based diagnostics and therapeutics, announced today it has successfully completed the prevalidation phase for its first diagnostic test. Using a single microRNA, the test is designed to differentiate squamous from non-squamous lung cancer with high sensitivity and specificity.
Rosetta Genomics diagnostic tests are currently undergoing validation testing at Columbia University Medical Center at its Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. The company expects three diagnostic tests to be launched in 2008 including a test for cancer of unknown primary, lung cancer vs. mesothelioma, and the squamous vs. non-squamous lung cancer test which has recently passed the prevalidation phase.
"The results we have seen so far for our microRNA-based diagnostic tests are very encouraging," Said Amir Avniel, President and CEO of Rosetta Genomics. "Results of the prevalidation phase showed the test differentiated squamous from non-squamous lung cancer using microRNA biomarkers identified by us, with both high sensitivity and specificity. We expect the test to be available for clinical use in the first half of 08."
About microRNAs
MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.
About Rosetta Genomics
Rosetta Genomics is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and other diseases
Source: Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product. Money.CNN.com PRNewswire-FirstCall (30 October 2007) [FullText and Forward-Looking Statement]
0 Comments:
Post a Comment
<< Home